Equities research analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.
Moleculin Biotech Stock Performance
NASDAQ:MBRX opened at $2.36 on Tuesday. Moleculin Biotech has a 12-month low of $2.12 and a 12-month high of $15.75. The company’s 50-day moving average is $3.00 and its two-hundred day moving average is $4.66.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.10) by ($0.13). Analysts forecast that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Moleculin Biotech
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Further Reading
- Five stocks we like better than Moleculin Biotech
- How to invest in marijuana stocks in 7 stepsĀ
- Why Block’s Key Components Make It a Solid Investment Choice
- Market Cap Calculator: How to Calculate Market Cap
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Overbought Stocks Explained: Should You Trade Them?
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.